Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. (Nasdaq: VANI) is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants based on its NanoPortal™ platform, along with neuromodulation devices through its Cortigent subsidiary. The VANI news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Vivani’s clinical programs, financings, and corporate actions evolve over time.
Recent Vivani news has highlighted progress with NPM-139, a semaglutide GLP-1 implant program for chronic weight management, including plans for a Phase 1 clinical study and preparations for a potential Phase 2 dose-ranging trial, subject to regulatory clearance and supportive data. The company has also reported results from the LIBERATE-1 Phase 1 study of its exenatide implant NPM-115, which it describes as the first-in-human application of the NanoPortal technology, as well as preclinical data suggesting sustained weight loss from a single NPM-139 implant in ongoing studies.
In addition to R&D updates, Vivani’s news flow includes announcements of equity financings, such as private placements and a registered direct offering of common stock, with stated use of proceeds for research, clinical development, working capital and general corporate purposes. The company also issues news about its proposed spin-off of Cortigent, Inc., which develops brain implant devices like the Orion® visual cortical prosthesis system and a stroke recovery neurostimulation platform.
Investors and followers of VANI can use this page to monitor clinical milestones, capital-raising transactions, conference presentations, and key steps in the Cortigent spin-off process, all drawn from Vivani’s own press releases and related regulatory communications.
Vivani (NASDAQ: VANI) announced that subsidiary Cortigent presented 6-year Early Feasibility Study results for the Orion visual cortical prosthesis at NANS 2026. Six subjects implanted 2018–2019 completed the study in March 2025, showing improved visual test performance with devices functional and <4% electrode loss.
One early seizure occurred; stimulation was adjusted and no further serious adverse events were reported. Cortigent plans to discuss a larger pivotal trial with the FDA in 2026.
Vivani Medical (Nasdaq: VANI) closed a registered direct offering and a concurrent private placement on January 27, 2026, selling a combined 3,040,551 shares at $1.48 per share for gross proceeds of approximately $4.5 million before fees and expenses. The private placement included 1,351,351 shares purchased by Chairman Gregg Williams. Proceeds are intended to fund ongoing research and clinical development of NanoPortal implants, plus working capital and general corporate purposes. ThinkEquity acted as sole placement agent for the registered offering.
Vivani Medical (Nasdaq: VANI) priced a best-efforts registered direct offering of 1,689,200 shares and a concurrent private placement of 1,351,351 shares at $1.48 per share.
Gross proceeds are expected to be approximately $4.5 million before fees and expenses. The private placement purchaser is Gregg Williams, chairman of the board. The offerings are expected to close on or about January 27, 2026, and net proceeds will fund research and clinical development, working capital and general corporate purposes.
Vivani (NASDAQ: VANI) subsidiary Cortigent will present an award-winning poster on Jan 23, 2026 at the North American Neuromodulation Society annual meeting describing the investigational Orion Visual Cortical Prosthesis System. The company says Orion completed a six-year Early Feasibility Study and is designed to elicit visual phosphenes via a 60-electrode cortical surface array paired to an implantable pulse generator with 60 outputs in a package about the size of three stacked dimes and a wireless wearable for real-time processing.
The poster highlights miniature, high-channel-count stimulation and real-time parameter control; it notes the electrode design derives from retinal implant experience with Argus II, which remained functional in retinal tissue for >17 years and was the only FDA-approved artificial vision device.
Vivani Medical (Nasdaq: VANI) reported third quarter 2025 results and a business update on Nov 13, 2025. The company completed LIBERATE-1, its first human test of the NanoPortal implant, and reported preclinical NPM-139 data showing 20% weight loss sustained for over 7 months. Vivani plans to initiate a Phase 1 semaglutide implant study in the first half of 2026 and is preparing a Phase 2 dose-ranging study pending Phase 1 results and regulatory feedback.
Financings in 3Q and October generated approximately $25.7 million in cash and commitments to support NPM-139 development and, as of Sept 30, 2025, Vivani held $4.0 million in cash. The company expects to complete the spin-off of Cortigent after the SEC resumes operations.
Vivani Medical (Nasdaq: VANI) closed a registered direct offering of 6,000,000 common shares and a concurrent private placement of 3,703,703 common shares on Oct 28, 2025 at $1.62 per share, generating approximately $15.7 million gross before fees and expenses.
The private placement purchaser was Gregg Williams, Chairman of Vivani’s board. The offerings were priced at-the-market under Nasdaq rules and used a Form S-3 shelf registration declared effective May 3, 2024. Net proceeds are intended to fund research and clinical development, plus working capital and general corporate purposes.
Vivani Medical (Nasdaq: VANI) priced a best-efforts registered direct offering of 6,000,000 common shares and a concurrent private placement of 3,703,703 common shares to Gregg Williams at $1.62 per share.
The combined gross proceeds are expected to be approximately $15.7 million before fees and expenses; closing is expected on or about October 28, 2025, subject to customary conditions. ThinkEquity is sole placement agent. Proceeds are intended to fund ongoing research and clinical development, plus working capital and general corporate purposes.
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn, Ph.D. will present at the ThinkEquity Conference on October 30, 2025 in New York.
Presentation is scheduled for 1:30 p.m. Eastern Time at the Lotus Suite East, Mandarin Oriental Hotel, 80 Columbus Circle. A webcast will be available on the company Investors page and via the provided Summitcast link.
Vivani Medical (NASDAQ: VANI) announced on Oct 3, 2025 that it has temporarily withdrawn the previously announced record date for the planned spin-off of its wholly owned subsidiary Cortigent, which develops brain implant neuromodulation devices. The withdrawal is due to delays arising from the current shutdown of the U.S. federal government. Vivani expects to reestablish and announce a new record date as soon as possible. The press release notes that ThinkEquity is acting as exclusive financial advisor to Cortigent for the spin-off transaction and provides a link to ThinkEquity for more information.
Vivani Medical (NASDAQ: VANI), a clinical-stage biopharmaceutical company focused on developing miniature, ultra long-acting drug implants, will present at the Emerging Growth Conference 86 on September 25, 2025.
Company President and CEO Adam Mendelsohn, Ph.D. will deliver a 30-minute presentation starting at 1:45 PM Eastern Time, providing a company overview followed by a Q&A session. Investors, analysts, and advisors are invited to participate in this interactive online event, with the opportunity to submit questions in advance to Questions@EmergingGrowth.com.
FAQ
What is the current stock price of Vivani Medical (VANI)?
What is the market cap of Vivani Medical (VANI)?
